Physician profile
Ernest Gregory Eckenrode
NPI 1659049526
$10,362.62
in general payments reported to CMS, 2019-2025
27 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $2,453 · 2023: $1,935 · 2024: $2,663 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,192 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,191.93 |
| Education | $349.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,469.44 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $1,257.46 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,118.97 | 2021-2025 | Dupixent |
| Abbvie INC. | $1,039.71 | 2022-2025 | |
| Ucb, INC. | $744.98 | 2022-2025 | Bimzelx |
| Lilly USA, LLC | $647.86 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $586.23 | 2021-2025 | |
| Genzyme Corporation | $465.81 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $433.51 | 2022-2025 | Sotyktu |
| Incyte Corporation | $422.83 | 2021-2025 | Opzelura |
| Pfizer INC. | $332.75 | 2022-2025 | |
| Leo Pharma INC. | $285.63 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $249.16 | 2021-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $248.17 | 2023-2025 | Cabtreo, Arazlo, Jublia |
| Dermavant Sciences, INC. | $243.90 | 2022-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $175.38 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $144.78 | 2023-2024 | Ycanth |
| Almirall LLC | $117.50 | 2021-2024 | Klisyri |
| Janssen Scientific Affairs, LLC | $88.22 | 2022 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Epi Health, LLC | $52.55 | 2021 | |
| Amgen INC. | $46.59 | 2023-2025 | Otezla, Otezla |
| Journey Medical Corporation | $28.68 | 2022-2023 | |
| Sebela Pharmaceuticals INC. | $28.52 | 2022 | |
| Lnhc, INC | $21.89 | 2025 | Zelsuvmi |
| Smith+Nephew, INC. | $15.71 | 2025 | Collagenase Santyl |
| Organon LLC | $11.39 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Eckenrode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.